Warren Buffett's holding company has disclosed its first biotechnology investment.
Patients with HER2-positive breast cancer could have a new treatment option from Seattle Genetics this summer.
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
The fourth-quarter report wasn't great, but there are signs that a turnaround is underway.
The growing healthcare conglomerate outperformed forecasts in the fourth quarter, and boosted its outlook for the year ahead.
Seattle Genetics posted eye-popping data from a study of patients given a combination of Padcev and Keytruda.
The Food and Drug Administration will expedite its review of capmatinib.
Gilead's next cell-based therapy could become a new lymphoma treatment option this summer.
The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.
Better than expected performances from new drugs and Humira gave investors plenty to look forward to in 2020.
The pharmaceutical giant's fourth-quarter 2019 earnings were disappointing, but there were things for investors to smile about in the new details on its upcoming spinoff.
Another $200 million investment from Nestle will turbocharge Palforzia's commercial launch.
One of Canada's largest cannabis producers is taking a big step back.
A rare public meeting to discuss the testing of personal care products for asbestos was informative and disturbing.
This more than triples the amount of medical marijuana that Aurora can export to Germany and the rest of the European Union.
Some of the biopharma industry's biggest names are taking important steps to combat the world's latest public health emergency.
Despite a poorly received fourth-quarter earnings report, Pfizer's the industry's best dividend-paying stock.
A pair of deals will remove some regulatory impediments to the merger.
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
A jury that told Gilead Sciences to pay $752 million worth of patent infringement damages didn't go as far as necessary, says Bristol-Myers Squibb.